Century Therapeutics 주식 (NASDAQ: IPSC)

에 대한 최신 뉴스 Century Therapeutics (NASDAQ:IPSC) 주식

Century Therapeutics

Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

Equities

Markets

IPSC

센추리 테라퓨틱스(NASDAQ:IPSC) 주가는 수요일(27일)에 20.74% 상승한 주당 1.63달러로 마감하면서, 10월 1일 이후 거의 한 달 만에 가장 높은 가격 변동폭을 기록했다. 또한 주가는 2023년 12월 6일 이후 11개월여 만에 하루 만에 가장 큰 폭으로 상승한 것이다.

센추리 테라퓨틱스, 캐스딘 캐피털이 지분 5.4%로 높이면서 주가 20% 폭등

Century Therapeutics, Inc. - Common Stock

Century Therapeutics Inc

ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan.

News

AVBP

ArriVent BioPharma Entered Exclusive License With Lepu Biopharma For MRG007, An Antibody Drug Conjugate For Treatment Of Gastrointestinal Cancers

Immutep Limited ((ASX: IMM, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that patient enrolment has been completed in the investigatorinitiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha (efti) in combination with radiotherapy plus KEYTRUDA&#xAE; (pembrolizumab) in the neoadjuvant setting for patients with resectable soft tissue sarcoma (STS). The Phase II trial conducted by the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients

IMMP

Immutep Reported Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

A highly publicized ban of TikTok by the U.S. led to other apps getting caught in the crossfire, including a game featuring Marvel superheroes. Here's a look at what happened and what the<a href="https://www.benzinga.com/general/social-media/25/01/43088960/trump-suspends-us-tiktok-ban-for-75-days-with-executive-order-but-legal-and-market-uncertainty-looms-over-platforms-future"> executive order signed</a> by President Donald Trump means for the game's future.
What Happened: The Supreme Court recently <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">upheld a ban</a> on TikTok in the U.S., following a congressional ruling that parent company ByteDance would have to divest the U.S. division of the company by Jan. 19.
While TikTok <a href="https://www.benzinga.com/25/01/43076609/tiktok-back-online-in-us-after-trump-vows-monday-executive-order">went dark briefly </a>over the weekend, an executive order signed by Trump provided an additional lifeline for ByteDance for 75 days.
Along with TikTok going dark on app stores from Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) as part of the pending ban, other apps owned by ByteDance companies also disappeared from the stores and for a brief time were unusable.
This includes Marvel Snap, a mobile collectible card <a href="https://www.marvelsnap.com/home">game </a>that features characters from the Marvel Universe. The game was developed by Second Dinner and published by Nuverse, a ByteDance subsidiary, in 2022, as <a href="https://www.usatoday.com/story/tech/news/2025/01/19/tiktok-ban-lemon8-capcut-marvel-snap/77825175007/">reported </a>by USA Today.
The game uses Marvel characters from the comic book company owned by Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).
A search for Marvel Snap on the Google Play Store Tuesday brought up other Marvel titles with the app still <a href="https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone">unavailable for download</a>. Existing owners of the app saw service restored in the U.S, as <a href="https://www.theverge.com/2025/1/20/24348353/marvel-snap-tiktok-ban-back-online">reported </a>by The Verge. The ban also impacted the PC version of the game, according to the company's announcement of the ban.
"Unfortunately, Marvel Snap is temporarily unavailable in U.S. app stores and is unavailable to play in the U.S. In a surprise to Second Dinner and our publisher Nuverse, Marvel Snap was affected by the takedown of TikTok late on Saturday, January 18," Second Dinner <a href="https://marvelsnapzone.com/marvel-snap-is-banned-in-the-united-states/">said </a>previously.
Second Dinner Chief Development Officer Ben Brode told followers on social media that no warning was given to the company or Nuverse that their app would be part of the ban.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent012125">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The ban of ByteDance apps was a large talking point mainly around TikTok, but several other apps were hurt by the ruling and are now affected.
Along with Marvel Snap, here are some other apps that ByteDance owns or controls that faced a similar fate.
<ul>
<li>Lemon8: social media platform</li>
<li>CapCut: video editing software</li>
<li>Gauth: artificial intelligence homework aid</li>
<li>Hypic: photo editing software</li>
<li>Lark: enterprise collaboration platform</li>
</ul>
Based on the timing of the ban still pending, these apps and the Marvel game could continue to be disallowed in app stores and could go dark in the future.
Second Dinner is ready to ensure this doesn't happen again by making changes.
"Marvel Snap is back online in the U.S. But to make sure this NEVER happens again, we're working to bring more services in-house and partner with a new publisher. This is the start of a new era for Marvel Snap." the company <a href="https://x.com/seconddinner/status/1881535498709266691">shared </a>on social media.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42654769/tiktok-ban-under-trump-president-elect-wants-to-keep-months-after-pelosi-said-follow-the-money">TikTok Ban Under Trump? President-Elect Reconsiders As Pelosi Says &#8216;Follow The Money&#8217;</a></li>
</ul>
Photo: Mino Surkala via Shutterstock

Entertainment

Gaming

Government

Social Media

Politics

AAPL

GOOG

GOOGL

Marvel Mobile Game Goes Dark After TikTok Ban: How Disney's Superhero Brand Got Caught Up In US Vs. China Battle

PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) has outperformed the market over the past 5 years by 10.01% on an annualized basis producing an average annual return of 23.27%. Currently, PDD Holdings has a market capitalization of $144.22 billion. 
Buying $1000 In PDD: If an investor had bought $1000 of PDD stock 5 years ago, it would be worth $2,789.23 today based on a price of $103.85 for PDD at the time of writing.
<h3>PDD Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737503109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Citigourp Global Markets 2% Protected Notes Linked To The Djia

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

As the oldest members of <a href="https://www.benzinga.com/personal-finance/24/12/42325436/despite-having-the-highest-income-gen-x-also-carries-the-most-debt-explaining-their-rock-bottom-consumer-sentiment">Generation X</a> (those born between 1965 and 1980) approach retirement, financial experts warn that many in this group may not be as prepared as they think. Generation X faces unique challenges as they prepare for retired life, from shortfalls in savings to unexpected costs that may arise.&nbsp;
Here's what experts say Gen Xers need to know to avoid these key pitfalls and ensure a more <a href="https://www.benzinga.com/personal-finance/24/11/41918104/are-you-on-track-to-retire-rich-heres-the-nest-egg-you-need-to-be-considered-a-wealthy-retiree">secure retirement</a>.&nbsp;
<h2 class="wp-block-heading">Look At Your Savings Goals</h2>
Many Gen Xers are significantly behind in their retirement savings. A recent study by Northwestern Mutual found that only 7% of Gen X respondents have saved more than 10 times their annual income–the amount most experts recommend for a comfortable retirement.&nbsp;
Don't Miss:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">but what&#8217;s driving it?</a></li>
</ul>
Perhaps even more concerning, over half of Gen X respondents say they have only saved three times their annual income or less. Fidelity recommends having at least three times your annual salary by age 40, six times your salary by age 50 and eight times your salary by age 60 to stay on track for a comfortable retirement.&nbsp;
This shortfall in savings is compounded by the fact that many Gen Xers do not have a <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/11/41702991/americans-worried-theyll-mess-up-retirement-income-planning-almost-half-fear-">retirement income plan</a>. According to Allianz, only 30% of Gen Xers have mapped out how they will fund their post-work years, the lowest rate among all generations surveyed.
<h2 class="wp-block-heading">Taxes and Healthcare Expenses</h2>
A common misconception among Americans is that taxes decrease in retirement. However, financial experts caution that many Gen Xers could face higher-than-expected tax burdens. The reason? Most have their retirement savings in tax-deferred accounts, like <a href="https://www.benzinga.com/personal-finance/24/11/42154984/new-findings-show-iras-and-401ks-contribute-less-than-20-of-retirees-income">401(k)s and IRAs</a>, which require taxes to be paid upon withdrawal.&nbsp;
"The big problem is that a lot of them are going to be faced with a lot of taxes in retirement," Jonathan Dane, founder and chief investment officer for Defiant Capital Group in Pittsburgh, told U.S. News. He says one way to mitigate this is to stop putting money in tax-deferred accounts and transition to Roth accounts, which allow for tax-free withdrawals.
See Also: The Biggest Disruption to IP since Disney — <a href="https://www.benzinga.com/money/elf-labs-1">Get in now as they monetize a $2 Trillion market by building content around the most profitable Character IP in history and combining it with the Patented Technology IP of the future.</a>
Another concern is healthcare costs. While Medicare provides comprehensive coverage starting at age 65, it doesn't cover everything. Long-term care expenses, like assisted living, typically aren't included. Experts suggest considering long-term care insurance or using a health savings account (HSA) to prepare for these costs.&nbsp;
<h2 class="wp-block-heading">Budgeting and Withdrawal Strategies</h2>
Financial planners warn that many Gen Xers don't clearly understand their spending habits. "They've been getting a paycheck for the last 40 years and they just don't know what they spend," Zach Ungerott of Hightower Wealth Advisors told U.S. News.
Knowing when and how much to withdraw from savings can make a significant difference. Starting withdrawals at age 59 ½ allows penalty-free access to funds in tax-advantaged accounts, but withdrawing too much too quickly risks prematurely depleting savings.
Trending: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
<h2 class="wp-block-heading">Updating Estate Plans and Investments</h2>
Many Gen Xers have outdated estate plans that don't reflect their current wishes. Reviewing and updating wills, beneficiary designations and other documents is essential to ensure assets are distributed as intended.
Investment strategies may also need adjustment. While Gen X has benefited from stock market gains, experts suggest diversifying into more stable assets like bonds or annuities to protect against market downturns.
With retirement on the horizon, Generation X has limited time to close savings gaps, reassess strategies and prepare for potential obstacles. Working with a <a href="https://www.benzinga.com/money/best-online-financial-advisors">financial professional</a> can help this generation create a plan tailored to their needs, ensuring they are better positioned for a secure retirement.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/planning-your-retirement-new-changes-to-social-security-in-2025-could-affect-you">Planning Your Retirement? New Changes To Social Security In 2025 Could Affect You</a></li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Personal Finance

'It Won't Be Enough': Financial Experts Warn Gen X About Key Retirement Pitfalls

Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) has outperformed the market over the past 5 years by 20.28% on an annualized basis producing an average annual return of 33.54%. Currently, Fortinet has a market capitalization of $74.35 billion. 
Buying $100 In FTNT: If an investor had bought $100 of FTNT stock 5 years ago, it would be worth $411.90 today based on a price of $97.00 for FTNT at the time of writing.
<h3>Fortinet's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737502210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTNT

$100 Invested In Fortinet 5 Years Ago Would Be Worth This Much Today

According to the latest data from the Centers for Disease Control and Prevention, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus. The virus was confirmed on Friday at a commercial poultry production facility in Georgia, the nation's top state <a href="https://www.benzinga.com/general/biotech/25/01/43046294/bird-flu-raising-red-flags-among-health-officials-cdc-urges-faster-testing">for chicken production. </a>
What To Know: The CDC said that the current public health risk is low and the agency is watching the situation carefully and monitoring people with animal exposures. Bird flu is "widespread in wild birds worldwide and is causing outbreaks in poultry and U.S. dairy cows with several recent human cases in U.S. dairy and poultry workers," the CDC stated in its <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">most recent</a> update.&nbsp;
On Friday, the Georgia Department of Agriculture announced it <a href="https://agr.georgia.gov/avian-influenza">detected</a> a case of Highly Pathogenic Avian Influenza at a commercial poultry producer in the state. The case marks the first in Georgia, the nation's top state for chicken production, since the 2022 countrywide outbreak. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a>
"This is a serious threat to Georgia's #1 industry and the livelihoods of thousands of Georgians who make their living in our state's poultry industry," Georgia Agriculture Commissioner Tyler Harper said in a news release.&nbsp;
According to an AP News<a href="https://apnews.com/article/bird-flu-georgia-chicken-commercial-flock-a5bcad4662d4cf60212f6acb4a55d2ad"> report,</a> the bird flu virus has been detected in 84 commercial and backyard flocks in the past month with 10.7 million birds affected. The virus has also been confirmed in dozens of dairy farms.
What Else: On Friday, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) announced <a href="https://www.benzinga.com/general/biotech/25/01/43105845/why-is-moderna-stock-trading-higher-on-tuesday-2">it received</a> an additional $590 million award from the U.S. Department of Health and Human Services (HHS) to accelerate the development of its mRNA-based influenza vaccines, including bird flu.
In 2023, Moderna commenced a Phase 1/2 study to generate safety and immunogenicity data for an investigational pandemic influenza vaccine (mRNA-1018) candidate against the H5 and H7 avian influenza viruses. Based on the preliminary data from the Phase 1/2 study, Moderna is preparing to advance mRNA-1018 into Phase 3. 
Other pharmaceutical companies, including Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), have bird flu vaccine candidates currently in clinical trials. 
CureVac BV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) started a phase I/II study on its bird flu vaccine candidate developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>). 
Egg producer Cal-Maine Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NYSE">CALM</a>) reported<a href="https://www.benzinga.com/news/earnings/25/01/42862269/cal-maine-foods-stock-climbs-after-strong-q2-results-eps-beat-revenues-beat"> its most recent </a>quarterly revenue of $954.7 million, well above the  $751.49 million consensus estimate, due in part to restricted supply resulting from highly pathogenic avian influenza (HPAI) outbreaks. Cal-Maine Foods stock gained more than 75% over the past six months. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/initiation/25/01/43102452/roku-analyst-sees-25-upside-as-tv-ad-dollars-go-digital">Roku Analyst Sees 25% Upside As TV Ad Dollars Go Digital&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

General

CALM

CVAC

MRNA

NVAX

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has outperformed the market over the past 15 years by 11.59% on an annualized basis producing an average annual return of 23.61%. Currently, Super Micro Computer has a market capitalization of $19.00 billion. 
Buying $100 In SMCI: If an investor had bought $100 of SMCI stock 15 years ago, it would be worth $2,795.00 today based on a price of $32.45 for SMCI at the time of writing.
<h3>Super Micro Computer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737501309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMCI

Here's How Much $100 Invested In Super Micro Computer 15 Years Ago Would Be Worth Today

An executive order signed by President Donald Trump put an emphasis on ending electric vehicle plans put in place by former President Joe Biden and could put an end to the $7,500 tax credits that helped <a href="https://www.benzinga.com/electric-vehicles">boost the sector.</a>
What Happened: One of Trump's first tasks since becoming president <a href="https://www.benzinga.com/tech/25/01/43090016/here-are-the-evs-which-could-lose-7500-ev-tax-credit-under-trump-administration">was to sign </a>the "Unleashing American Energy" executive order.
Trump's order says he is eliminating the "electric vehicle mandate" and also terminating the Green New Deal.
While Trump may need additional approval to end the $7,500 tax credit American consumers can currently get for buying numerous electric vehicle models, including several from Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), the order pauses the disbursement of funds that were part of the Inflation Reduction Act of 2022.
The electric vehicle tax credits have helped boost sales of EVs over the past several years, including Tesla. Once a beneficiary of tax credits for his company, Tesla CEO Elon Musk has changed his tune about the credits in recent years.
Musk <a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably">said recently</a> that he was okay with the tax credits going away and has pledged his support to Trump, who he supported during the 2024 presidential election.
In a quarterly earnings call in July 2024, Musk said Trump winning the election and the end of the tax credits could be "devastating" for Tesla rivals, but would likely end up being a long-term positive for his company. &nbsp;
"Long term probably actually helps Tesla, would be my guess, yes," Musk said at the time.
With the potential of the EV tax credits going away, Tesla influencer Sawyer Merritt conducted a poll on social media platform X to see if people thought the move would help or hurt Tesla.
"Long-term is the U.S. EV credit disappearing bullish, bearish, or neutral for Tesla," Merritt asked.
Here are the poll <a href="https://x.com/SawyerMerritt/status/1881777072017649722">results</a>, based on 16,294 votes.
<ul>
<li>Bullish: 40.4%</li>
<li>Neutral: 27.5%</li>
<li>Bearish: 19.4%</li>
<li>See Results: 12.6%</li>
</ul>
The largest percentage of voters believe the EV tax credit going away would be bullish for Tesla. This is likely related to the belief that the move would be bad for most EV companies, but hurt Tesla's competitors more. Tesla has profitability per vehicle and vertical integration for manufacturing, which helps the company on costs and scale.
When asked for his opinion, Merritt said he was neutral on the potential change.
"Hard to argue that it's really bullish since Tesla is currently the largest beneficiary of the EV credit, but it disappearing I don't think will be a negative as some are suggesting. Tesla is no doubt in the strongest position to withstand the impact of it disappearing vs their legacy auto competition," Merritt said.
Read Also: <a href="https://www.benzinga.com/news/global/25/01/43088582/gary-black-questions-elon-musks-take-on-ev-credit-removal-after-tesla-sales-drop-in-europe-not-sure-how-the-math-works">Gary Black Questions Elon Musk&#8217;s Take On EV Credit Removal After Tesla Sales Drop In Europe: &#8216;Not Sure How The Math Works&#8217;</a>
Why It's Important: Musk's stance on being against tax credits that help boost the market share of electric vehicle companies could be a surprise to many given his past support for the sector.
"Since the company's inception in 2003, Tesla's mission has been to accelerate the world's transition to sustainable energy," Tesla's website <a href="https://www.tesla.com/elon-musk">reads</a>.
Musk has said in the past that the acceleration of sustainable energy is fundamental to the future of humanity, as reported by <a href="https://www.cnbc.com/2019/02/04/elon-musk-on-the-why-and-purpose-behind-tesla.html#:~:text=We%20created%20Tesla%20to%20accelerate,for%20humanity%2C%22%20Musk%20said.">CNBC</a>.
These days, Musk and Tesla are focusing heavily on autonomous vehicles which could be the next political move by the Trump administration. Trump<a href="https://www.benzinga.com/general/politics/24/10/41298125/maybe-musk-missed-the-memo-trumps-plan-to-ban-autonomous-vehicles-could-sour-friendship"> previously said he </a>would ban autonomous vehicles from American roads.
Since then, Trump may have reversed his stance and come around to help boost the future of Musk's company by pushing autonomous vehicle testing forward and making Tesla's vision a reality.
Musk has watched his wealth soar <a href="https://www.benzinga.com/news/management/24/12/42444955/elon-musk-first-person-worth-400-billion-as-tesla-stock-hits-new-all-time-highs-how-2024-election-helped-could-lead-to-future-gains">to over $400 billion</a> since Trump won the 2024 presidential election.
While the new EV tax credit rules could be bad for the electric vehicle sector over time, the current president is likely going to be good for Musk and his company. The question is what the short and long-term impacts on Tesla will be. Based on the poll, investors don't seem too concerned about the potential loss of EV tax credits.
TSLA Price Action: Tesla stock closed down 0.57% to $424.07 on Tuesday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is up 103% over the last year. Tesla's drop came while many stocks were up on the first trading day after Trump's inauguration with the SPDR S&amp;P 500 ETF up 0.92% to $603.05 Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42986863/us-electric-vehicle-sales-hit-record-1-3-million-units-in-2024-despite-tesla-declines-top-10-bestsel">US Electric Vehicle Sales Hit Record 1.3 Million Units In 2024, Despite Tesla Declines: Top 10 Bestselling Models</a></li>
</ul>
Photo: Courtesy Tesla

TSLA

Trump's Plan To End $7,500 EV Tax Credits Could Be 'Devastating' For Telsa Rivals, Poll Says Could Be Bullish For Elon Musk's Company

Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) has outperformed the market over the past 20 years by 3.08% on an annualized basis producing an average annual return of 11.6%. Currently, Lockheed Martin has a market capitalization of $118.93 billion. 
Buying $100 In LMT: If an investor had bought $100 of LMT stock 20 years ago, it would be worth $897.68 today based on a price of $506.00 for LMT at the time of writing.
<h3>Lockheed Martin's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737500410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Lockheed Martin 20 Years Ago Would Be Worth This Much Today

This is subject to the completion of the Reverse Stock Split.

GSAT

Globalstar Intends To Voluntarily Delist From NYSE American And Transfer To Nasdaq

The data will be presented in a poster session (abstract #206) at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer Symposium (ASCO GI) being held January 23-25, 2025, in San Francisco.
"We are very encouraged by the initial Phase 2 proof-of-concept data for the combination of vilastobart and atezolizumab in heavily pre-treated patients with MSS colorectal cancer, including partial responses accompanied by marked decreases in tumor biomarkers and improvement in clinical symptoms," said Katarina Luptakova, M.D., chief medical officer of Xilio.

Xilio Reports Initial Data From Ongoing Phase 2 Clinical Trial Evaluating Vilastobart In Combination With Atezolizumab; 27% Preliminary Response Rate Observed In Heavily Pre-Treated Microsatellite Stable Colorectal Cancer Patients Without Liver Metastases

The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is subject to market and other conditions and the completion of the SEC's review process.

IPOs

Voyager Technologies Submits Confidential Registration Statement For Proposed IPO

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 19.56% on an annualized basis producing an average annual return of 28.09%. Currently, Intuitive Surgical has a market capitalization of $215.49 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 20 years ago, it would be worth $13,941.23 today based on a price of $605.00 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737499516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

Here's How Much $100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth Today

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) has outperformed the market over the past 5 years by 3.68% on an annualized basis producing an average annual return of 16.95%. Currently, East West Bancorp has a market capitalization of $14.38 billion. 
Buying $1000 In EWBC: If an investor had bought $1000 of EWBC stock 5 years ago, it would be worth $2,106.64 today based on a price of $103.71 for EWBC at the time of writing.
<h3>East West Bancorp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737498617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EWBC

Here's How Much You Would Have Made Owning East West Bancorp Stock In The Last 5 Years

Contracts

IAC Enters Further Amendment To Its Services Agreement With Google; Expiration Date Of Agreement Is Now March 31, 2026, With An Automatic Renewal For An Additional One-year Period - Filing

Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares are trading higher in Tuesday&#8217;s after-hours session after Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported better-than-expected <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">financial results for the fourth quarter</a>.
What Happened With Netflix: Netflix reported fourth-quarter revenue of $10.25 billion, beating analysts estimates of $10.11 billion. The streaming giant reported quarterly earnings of $4.27 per share, beating analyst estimates of $4.19 per share.
Shares appear to be soaring in response to the company&#8217;s strong subscriber growth. Netflix said it added 18.91 million paid subscribers in the quarter, bringing its total subscriber count up to 301.63 million.
Netflix noted that its advertising plan continues to be quite popular, generating over 55% of sign-ups in the quarter. The company&#8217;s ads plan grew nearly 30% on a quarter-over-quarter basis.
&#8220;We're on track to reach sufficient scale for ads members in all of our ads countries in 2025. A top priority in 2025 is to improve our offering for advertisers so that we can substantially grow our advertising revenue,&#8221; the company said. 
NFLX Earnings: <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">Netflix Q4 Earnings: Record Subscribers, NFL, &#8216;Squid Game&#8217; Push Past &#8216;Highest Expectations&#8217;</a>
Why It Matters For ROKU: Roku is well-positioned to benefit from strong advertising trends from Netflix and other streaming companies.
Roku creates revenue opportunities with streaming companies through partnerships and advertising. The company operates an advertising distribution platform, allowing it to capitalize on the growth of streaming. Netflix was reportedly <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/06/27622300/3-reasons-why-this-analyst-thinks-a-netflix-roku-deal-may-not-materialize" target="_blank" rel="noreferrer noopener">considering a takeover of Roku</a> a couple of years ago, but a deal never materialized.
Roku is due to report its <a href="https://www.benzinga.com/calendars/earnings">fourth-quarter financial results</a> in early February, although a date has not yet been confirmed by the company. Analysts expect Roku to report a loss of 41 cents per share and revenue of $1.15 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
ROKU Price Action: <a href="http://benzinga.com/quote/roku">Roku shares</a> were up 3.71% in after-hours, trading at $82.70 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

Media

NFLX

ROKU

Roku Stock Is Rising After-Hours Tuesday: Here's Why

As of January 17, 2025, a total of approximately 13.24 million shares remained available for repurchase under the existing repurchase authorization, resulting in an increase of 6.75 million shares of common stock available for repurchase.

Buybacks

HOMB

Home BancShares Increases Share Repurchase Program And Renew Authorization To 20M Shares

Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively.
Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients.
In addition to the data shared at ASCO GI, Oncodetect achieved its primary endpoint in the Beta-CORRECT study.&nbsp;
&nbsp;
&nbsp;

EXAS

Exact Sciences Says Oncodetect Test Achieved Primary Endpoint In Second Clinical Validation Study, Extending Prognostic Value Into Stages II And IV Colon Cancer And Rectal Cancer

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 18.61%. Currently, Centene has a market capitalization of $32.14 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $13,092.03 today based on a price of $63.66 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737497710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much Today

Chardan analyst Geulah Livshits lowered the firm's price target on Century Therapeutics (IPSC) to $11 from $17 and keeps a Buy rating on the shares...

Century Therapeutics price target lowered to $11 from $17 at Chardan

Century Therapeutics, Inc. (IPSC) has disclosed a new risk, in the Debt & Financing category. Century Therapeutics, Inc. does not currently face an...

Century Therapeutics, Inc. Demonstrates Strong Financial Management with No Senior Securities Defaults

Takeda in deal with Alloy Therapeutics to develop cell therapy platforms for cancer

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday. The company's shares c...

Leerink Partners Reaffirms Their Buy Rating on Century Therapeutics (IPSC)

The latest update is out from Century Therapeutics ( ($IPSC) ). Century Therapeutics announced that Bristol-Myers Squibb will terminate their colla...

Century Therapeutics Faces Termination of BMS Agreement

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Century Therapeutics (IPSC – Research Report), Incyt...

Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)

Piper Sandler lowered the firm's price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares. Century i...

Century Therapeutics price target lowered to $4 from $12 at Piper Sandler

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MetaVia (MTVA – Research Report) and Century Therape...

Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)

Sami Corwin, an analyst from William Blair, has initiated a new Hold rating on Century Therapeutics (IPSC). Sami Corwin has given his Hold rating d...

Cautious Optimism on Century Therapeutics: Promising Early-Stage Developments But Awaiting Further Data

Century Therapeutics (IPSC) has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas Mack...

Century announces investigator-initiated Phase 1/2 trial of CNTY-101

BCYC

INCY

MTVA

Health Care

Press Releases

Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting

Analyst Ratings

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

Earnings

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Management

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Clear Street Launches Healthcare & Biotechnology Equity Research

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

JANX

MLTX

NUVB

PTGX

YMAB

Aadi Bioscience

Adicet Bio

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Agenus

Allakos

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

bluebird bio

Cue Biopharma

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PepGen

Regulus Therapeutics

Skye Bioscience

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Vigil Neuroscience

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Piper Sandler

Chardan Capital

HC Wainwright & Co.

Canaccord Genuity

JP Morgan

센추리 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) 주가는 수요일(27일)에 20.74% 상승한 주당 1.63달러로 마감하면서, 10월 1일 이후 거의 한 달 만에 가장 높은 가격 변동폭을 기록했다. 또한 주가는 2023년 12월 6일 이후 11개월여 만에 하루 만에 가장 큰 폭으로 상승한 것이다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-668715" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-1024x251.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-1024x251.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-300x74.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-768x188.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-1536x376.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart.png 1738w" alt="" width="1024" height="251" /></figure>
무슨 일 있었나: 수요일 미 증권거래위원회(SEC) 공시에 따르면 캐스딘 캐피털은 바이오 기업 센추리 테라퓨틱스의 주식 1,380,000주를 추가로 인수하여 지분을 43% 가까이 늘렸다.
이러한 거래가 완료된 후 캐스딘 캐피털은 총 4,592,316주, 즉 5.4%의 센추리 테라퓨틱스 주식을 보유하게 되었다. 서류에 따르면 센추리 주식은 주당 1.35달러에 매입되었고, 거래 후 센추리 테라퓨틱스는 캐스딘 포트폴리오의 0.12%를 차지하게 되었다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%94%ED%98%B8%ED%99%94%ED%8F%90-%EC%95%A0%EB%84%90%EB%A6%AC%EC%8A%A4%ED%8A%B8-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C%EC%8A%A4%ED%8A%B8%EB%9E%98%ED%8B%B0%EC%A7%80%EC%9D%98-%EC%A0%84%ED%99%98/" target="_blank" rel="noopener">암호화폐 애널리스트, 마이크로스트레티지의 전환사채로 인한 청산 위험 경고</a>
왜 중요한가: 센추리 주가는 캐스딘의 추가 인수 이후 36% 급등했던 2023년 12월 6일 이후 일일 최대 상승을 기록하면서 21% 가까이 급등했다.
뉴욕에 본사를 둔 투자 회사 캐스딘 캐피털은 바이오 분야 투자를 전문으로 하는 회사다. 15억 달러 규모의 주식 포트폴리오를 보유하고 있으며, 주요 보유 종목으로는 바이오라이프 솔루션스(BLFS)와 사렙타 테라퓨틱스(SRPT)가 있다.
이미지 출처: Unsplash 
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Century Therapeutics

뉴스

에 대한 최신 뉴스 Century Therapeutics (NASDAQ:IPSC) 주식

목요일, 11월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌